Share This:
Search Results
The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:
- Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
- Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
- Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-032 | 3778-73-2 | Isophosphamide | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-053 | 121-66-4 | 2-Amino-5-nitrothiazole | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Positive | Positive | (LYMPHOMA, LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-058 | 52-24-4 | tris(Aziridinyl)-phosphine sulfide (Thio-TEPA) | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA, LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-058 | 52-24-4 | tris(Aziridinyl)-phosphine sulfide (Thio-TEPA) | Mice | B6C3F1 | Male | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA, LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-058 | 52-24-4 | tris(Aziridinyl)-phosphine sulfide (Thio-TEPA) | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| Yes | TR-039 | 303-34-4 | Lasiocarpine | Rats | F344/N | Female | Dosed-Feed | Hematopoietic System | Positive | Positive | Lymphoma/Leukemia | Neoplastic Lesions |
| Yes | TR-042 | 320-67-2 | 5-Azacytidine | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR GRANULOCYTIC SARCOMA) | Neoplastic Lesions |
| Yes | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| Yes | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| Yes | TR-078 | 21416-87-5 | ICRF-159 | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| Yes | TR-134 | 128-66-5 | C.I. Vat Yellow 4 | Mice | B6C3F1 | Male | Dosed-Feed | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| Yes | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Female | Dosed-Feed | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-144 | 117-79-3 | 2-Aminoanthraquinone | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| Yes | TR-155 | 88-06-2 | 2,4,6-Trichlorophenol | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Positive | Positive | (LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-162 | 95-80-7 | 2,4-Diaminotoluene (2,4-toluene diamine) | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Positive | Equivocal Evidence | (LYMPHOMA) | May Have Been Related |
| Yes | TR-213 | 85-68-7 | Butyl benzyl phthalate | Rats | F344/N | Female | Dosed-Feed | Hematopoietic System | Positive | Positive | LEUKEMIA 7/49 7/49 18/50 | Neoplastic Lesions |
| Yes | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Positive | Equivocal Evidence | LYMPHOMA 10/50 16/50 19/50 | May Have Been Related |
| Yes | TR-248 | 13552-44-8 | 4,4'-Methylenedianiline dihydrochloride | Mice | B6C3F1 | Female | Dosed-Water | Hematopoietic System | Positive | Positive | LYMPHOMA 13/50 28/50 29/50 | Neoplastic Lesions |
| Yes | TR-253 | 2835-39-4 | Allyl isovalerate | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Positive | Positive | LYMPHOMA 11/50 11/50 18/50 | Neoplastic Lesions |
| Yes | TR-253 | 2835-39-4 | Allyl isovalerate | Rats | F344/N | Male | Gavage | Hematopoietic System | Positive | Positive | LEUKEMIA 1/50 4/50 7/50 | Neoplastic Lesions |
| Yes | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Clear Evidence | Equivocal Evidence | LYMPHOMA 17/50 24/50 25/50 | May Have Been Related |
| Yes | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 1/50 10/49 10/49 | Neoplastic Lesions |
| Yes | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 0/50 23/50 29/50 | Neoplastic Lesions |
| Yes | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 15/49 25/45 26/50 22/49 | Neoplastic Lesions |
| Yes | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 4/49 10/48 10/50 15/49 | Neoplastic Lesions |
| Yes | TR-298 | 597-25-1 | Dimethyl morpholinophosphoramidate | Rats | F344/N | Female | Gavage | Hematopoietic System | Some Evidence | Some Evidence | LEUKEMIA 9/50 13/50 12/49 18/50 | Neoplastic Lesions |
| Yes | TR-298 | 597-25-1 | Dimethyl morpholinophosphoramidate | Rats | F344/N | Male | Gavage | Hematopoietic System | Some Evidence | Some Evidence | LEUKEMIA 14/50 21/50 19/50 25/50 | Neoplastic Lesions |
| Yes | TR-305 | 108171-27-3 | Chlorinated paraffins: C23, 43% chlorine | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 6/50 12/50 16/50 | Neoplastic Lesions |
| Yes | TR-308 | 108171-26-2 | Chlorinated paraffins: C12, 60% chlorine | Rats | F344/N | Male | Gavage | Hematopoietic System | Clear Evidence | Equivocal Evidence | LEUKEMIA 7/50 12/50 14/50 | May Have Been Related |
| Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80 | Neoplastic Lesions |
| Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50 | Neoplastic Lesions |
| Yes | TR-342 | 62-73-7 | Dichlorvos | Rats | F344/N | Male | Gavage | Hematopoietic System | Some Evidence | Some Evidence | LEUKEMIA 11/50 20/50 21/50 | Neoplastic Lesions |
| Yes | TR-366 | 123-31-9 | Hydroquinone | Rats | F344/N | Female | Gavage | Hematopoietic System | Some Evidence | Some Evidence | Leukemia 9/55 15/55 22/55 | Neoplastic Lesions |
| Yes | TR-311 | 127-18-4 | Tetrachloroethylene | Rats | F344/N | Female | Inhalation | Hematopoietic System | Some Evidence | Some Evidence | LEUKEMIA 18/50 30/50 29/50 | Neoplastic Lesions |
| Yes | TR-311 | 127-18-4 | Tetrachloroethylene | Rats | F344/N | Male | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LEUKEMIA 28/50 37/50 37/50 | Neoplastic Lesions |
| Yes | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Rats | F344/N | Male | Gavage | Hematopoietic System | Some Evidence | Some Evidence | LEUKEMIA 7/50 16/50 3/50 | Neoplastic Lesions |
| Yes | TR-416 | 91-23-6 | o-Nitroanisole | Rats | F344/N | Female | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 14/50 11/50 14/50 26/50 | Neoplastic Lesions |
| Yes | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 12/50 13/35 18/65 5/50 | May Have Been Related |
| Yes | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 1/60 3/45 6/75 4/60 | May Have Been Related |
| Yes | TR-416 | 91-23-6 | o-Nitroanisole | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 26/50 25/50 42/50 34/50 | Neoplastic Lesions |
| Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 7/50 13/35 27/65 15/50 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LEUKEMIA 13/50 14/50 20/50 | Neoplastic Lesions |
| Yes | TR-323 | 756-79-6 | Dimethyl methylphosphonate | Rats | F344/N | Male | Gavage | Hematopoietic System | Some Evidence | Equivocal Evidence | LEUKEMIA 10/50 11/50 17/50 | May Have Been Related |
| Yes | TR-402 | 110-00-9 | Furan | Rats | F344/N | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 8/50 9/50 17/50 21/50 | Neoplastic Lesions |
| Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 17/50 19/35 28/65 20/50 | May Have Been Related |
| Yes | TR-313 | 2385-85-5 | Mirex | Rats | F344/N | Female | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | LEUKEMIA 6/52 9/52 14/52 | Neoplastic Lesions |
| Yes | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 9/49 6/48 22/49 | Neoplastic Lesions |
| Yes | TR-340 | 5634-39-9 | Iodinated glycerol | Rats | F344/N | Male | Gavage | Hematopoietic System | Some Evidence | Some Evidence | LEUKEMIA 14/50 29/50 24/50 | Neoplastic Lesions |
| Yes | TR-402 | 110-00-9 | Furan | Rats | F344/N | Male | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 8/50 11/50 17/50 25/50 | Neoplastic Lesions |
| Yes | TR-391 | 115-96-8 | Tris(2-Chloroethyl) Phosphate | Rats | F344/N | Female | Gavage | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 14/50 16/50 20/50 | May Have Been Related |
| Yes | TR-391 | 115-96-8 | Tris(2-Chloroethyl) Phosphate | Rats | F344/N | Male | Gavage | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 5/50 14/50 13/50 | May Have Been Related |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60 | Neoplastic Lesions |
| Yes | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Male | Inhalation | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 16/50 23/50 29/50 25/50 | May Have Been Related |
| Yes | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 4/60 17/60 55/60 60/60 | Neoplastic Lesions |
| Yes | TR-540 | 7220-79-3 | Methylene blue trihydrate | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Some Evidence | Equivocal Evidence | MALIGNANT LYMPHOMA 2/50 2/50 2/50 5/50 | May Have Been Related |
| Yes | TR-450 | 116-14-3 | Tetrafluoroethylene | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | HISTIOCYTIC SARCOMA 1/48 21/48 19/47 18/48 | Neoplastic Lesions |
| Yes | TR-450 | 116-14-3 | Tetrafluoroethylene | Mice | B6C3F1 | Male | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | HISTIOCYTIC SARCOMA 0/48 12/48 7/48 7/48 | Neoplastic Lesions |
| Yes | TR-450 | 116-14-3 | Tetrafluoroethylene | Rats | F344/N | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA: 16/50 31/50 23/50 36/50 | Neoplastic Lesions |
| Yes | TR-537 | 631-64-1 | Water disinfection byproducts (Dibromoacetic acid) | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Some Evidence | Some Evidence | MONONUCLEAR CELL LEUKEMIA (ALL ORGANS) 11/50 13/50 16/50 22/50 | Neoplastic Lesions |
| Yes | TR-537 | 631-64-1 | Water disinfection byproducts (Dibromoacetic acid) | Rats | F344/N | Male | Dosed-Water | Hematopoietic System | Some Evidence | Some Evidence | MALIGNANT MESOTHELIOMA (ALL ORGANS) 3/50 1/50 0/50 10/50 | Neoplastic Lesions |
| Yes | TR-538 | 108-10-1 | Methyl isobutyl ketone | Rats | F344/N | Male | Inhalation | Hematopoietic System | Some Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 25/50 26/50 32/50 35/50 | May Have Been Related |
| Yes | TR-512 | 37319-17-8 | Elmiron (sodium pentosanpolysulfate) | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Some Evidence | Equivocal Evidence | MALIGNANT LYMPHOMA (ALL ORGANS) 7/50 8/50 6/50 16/50 | May Have Been Related |
| Yes | TR-533 | 119-61-9 | Benzophenone | Mice | B6C3F1/N | Female | Dosed-Feed | Hematopoietic System | Some Evidence | Some Evidence | HISTIOCYTIC SARCOMA: 0/50 0/50 5/50 3/50 | Neoplastic Lesions |
| Yes | TR-533 | 119-61-9 | Benzophenone | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Some Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 27/50 41/50 39/50 24/50 | May Have Been Related |
| Yes | TR-450 | 116-14-3 | Tetrafluoroethylene | Rats | F344/N | Male | Inhalation | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA: 34/50 43/50 38/50 31/50 | May Have Been Related |
| Yes | TR-465 | 77-09-8 | Phenolphthalein | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | HISTIOCYTIC SARCOMA 0/50 2/50 7/50 7/50; LYMPHOMA 15/50 28/50 33/5 25/50; LYMPHOMA (THYMIC ORIGIN) 1/50 9/50 10/50 7/50 | Neoplastic Lesions |
| Yes | TR-465 | 77-09-8 | Phenolphthalein | Mice | B6C3F1 | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | HISTIOCYTIC SARCOMA 1/50 3/50 11/50 12/49; LYMPHOMA (THYMIC ORIGIN) 0/50 4/50 7/50 2/49 | Neoplastic Lesions |
| Yes | TR-492 | 1303-00-0 | Gallium arsenide | Rats | F344/N | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 22/50 21/50 18/50 33/50 | Neoplastic Lesions |
| Yes | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Female | Inhalation | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 14/50 21/50 14/50 24/50 | May Have Been Related |
| Yes | TR-508 | 23246-96-0 | Riddelliine | Rats | F344/N | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA (ALL ORGANS) 12/50 8/50 13/50 18/50 18/50 14/50 | Neoplastic Lesions |
| Yes | TR-508 | 23246-96-0 | Riddelliine | Rats | F344/N | Male | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | Hematopoietic System: MONONUCLEAR CELL LEUKEMIA (ALL ORGANS) 2/50 9/50 | Neoplastic Lesions |
| Yes | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/60 2/60 3/60 50/60 | Neoplastic Lesions |
| Yes | TR-543 | 98-83-9 | alpha-Methylstyrene | Rats | F344/N | Male | Inhalation | Hematopoietic System | Some Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 26/50 32/50 29/50 38/50 | May Have Been Related |
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Brain | Clear Evidence | Equivocal Evidence | GLIOMA 0/50 2/48 1/49 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Brain | Clear Evidence | Clear Evidence | (STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Forestomach | Clear Evidence | Clear Evidence | PAPILLOMA 0/49 4/42 10/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 3/50 2/50 4/50 22/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR CARCINOMA 1/50 0/50 0/50 1/50 8/50 4/73, STOP STUDY 3/50 7/50 9/50 10/50 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Forestomach | Clear Evidence | Clear Evidence | PAPILLOMA 0/49 5/40 0/44 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50 | Neoplastic Lesions |
| Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80 | Neoplastic Lesions |
| Yes | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 1/50 10/49 10/49 | Neoplastic Lesions |
| Yes | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 0/50 23/50 29/50 | Neoplastic Lesions |
| Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Intestines (Small) | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/49 0/49 0/48 0/50 2/50 0/80 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/50 3/48 1/49 0/73, STOP STUDY 4/48 1/50 3/49 1/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 15/49 14/49 15/50 19/50 16/50 2/80 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/47 4/49 OR CARCINOMA 0/50 1/47 1/49 COMBINED 0/50 2/47 5/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 21/50 23/50 30/50 25/48 33/48 5/72, STOP STUDY 27/49 19/49 19/50 11/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 4/50 15/50 19/50 24/50 25/50 22/78 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 3/49 9/48 20/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 6/48 8/49 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 2/50 12/49 11/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 2/49 5/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 21/50 23/50 19/50 31/49 35/50 3/73, STOP STUDY 36/50 28/50 32/50 17/50 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ACINAR CELL CARCINOMA 0/50 2/49 6/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Ovary | Clear Evidence | Clear Evidence | BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 1/49 0/49 1/48 9/50 8/50 6/79; ADENOMA OR BENIGN MIXED TUMOR 2/49 4/49 1/48 4/50 6/50 2/79 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Ovary | Clear Evidence | Clear Evidence | GRANULOSA CELL TUMOR 0/49 6/45 12/48 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Preputial Gland | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL CARCINOMA 0/50 3/50 1/50 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Preputial Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 0/50 0/50 5/50 0/73, STOP STUDY 1/50 4/50 4/50 3/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Subcutaneous Tissue | Clear Evidence | Equivocal Evidence | NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 0/50 0/50 1/49 21/50 23/80 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 11/48 18/49 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 16/49 7/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 0/49 1/50 5/48 20/48 4/73, STOP STUDY 15/50 7/50 33/50 13/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Zymbal Gland | Clear Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 0/50 0/50 0/50 0/50 0/50 2/80 | May Have Been Related |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Zymbal Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 0/50 2/50 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Zymbal Gland | Clear Evidence | Equivocal Evidence | (STOP STUDY) CARCINOMA 1/50 0/50 2/50 2/50 | May Have Been Related |
| No | TR-053 | 121-66-4 | 2-Amino-5-nitrothiazole | Mice | B6C3F1 | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-053 | 121-66-4 | 2-Amino-5-nitrothiazole | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-053 | 121-66-4 | 2-Amino-5-nitrothiazole | Rats | F344/N | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| Yes | TR-053 | 121-66-4 | 2-Amino-5-nitrothiazole | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Positive | Positive | (LYMPHOMA, LEUKEMIA) | Neoplastic Lesions |
| No | TR-144 | 117-79-3 | 2-Aminoanthraquinone | Rats | F344/N | Female | Dosed-Feed | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| Yes | TR-144 | 117-79-3 | 2-Aminoanthraquinone | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| No | TR-144 | 117-79-3 | 2-Aminoanthraquinone | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-144 | 117-79-3 | 2-Aminoanthraquinone | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-144 | 117-79-3 | 2-Aminoanthraquinone | Rats | F344/N | Male | Dosed-Feed | Liver | Positive | Positive | (NEOPLASTIC NODULE OR CARCINOMA) | Neoplastic Lesions |
| No | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Mice | B6C3F1 | Male | Gavage | Unspecified | No Evidence | Not applicable | Not applicable | |
| No | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Rats | F344/N | Female | Gavage | Adrenal Gland Medulla | Some Evidence | Some Evidence | PHEOCHROMOCYTOMA 1/50 5/50 6/50 | Neoplastic Lesions |
| No | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Rats | F344/N | Male | Gavage | Adrenal Gland Medulla | Some Evidence | Some Evidence | PHEOCHROMOCYTOMA 18/50 25/50 22/49 OR MALIGNANT PHEOCHROMOCYTOMA 0/50 2/50 2/49 COMBINED 18/50 27/50 24/49 | Neoplastic Lesions |
| Yes | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Rats | F344/N | Male | Gavage | Hematopoietic System | Some Evidence | Some Evidence | LEUKEMIA 7/50 16/50 3/50 | Neoplastic Lesions |
| No | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Mice | B6C3F1 | Female | Gavage | Liver | Equivocal Evidence | Equivocal Evidence | ADENOMA 3/50 7/49 4/50 OR CARCINOMA 1/50 5/49 0/50 COMBINED 4/50 12/49 4/50 | Neoplastic Lesions |
| No | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Some Evidence | Some Evidence | ADENOMA 2/50 13/50 6/50 | Neoplastic Lesions |
| No | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Rats | F344/N | Female | Gavage | Pituitary Gland | Some Evidence | Some Evidence | ADENOMA 15/49 24/50 25/50 | Neoplastic Lesions |
| No | TR-332 | 149-30-4 | 2-Mercaptobenzothiazole | Rats | F344/N | Male | Gavage | Preputial Gland | Some Evidence | Some Evidence | ADENOMA 0/50 4/50 4/50 OR CARCINOMA 1/50 2/50 1/50 COMBINED 1/50 6/50 5/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 3/51 4/55 11/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Small) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/51 0/53 1/51 3/55 1/59 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 3/50 2/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 0/52 0/50 1/51 2/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 25/50 45/51 46/53 45/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | ADENOMA 1/51 2/53 4/51 3/53 3/59 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Seminal Vesicle | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/52 1/50 4/51 11/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Urinary Bladder | Clear Evidence | Clear Evidence | TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Unspecified) | Clear Evidence | Equivocal Evidence | HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60 | Neoplastic Lesions |
| No | TR-162 | 95-80-7 | 2,4-Diaminotoluene (2,4-toluene diamine) | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| Yes | TR-162 | 95-80-7 | 2,4-Diaminotoluene (2,4-toluene diamine) | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Positive | Equivocal Evidence | (LYMPHOMA) | May Have Been Related |
| No | TR-162 | 95-80-7 | 2,4-Diaminotoluene (2,4-toluene diamine) | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-162 | 95-80-7 | 2,4-Diaminotoluene (2,4-toluene diamine) | Rats | F344/N | Female | Dosed-Feed | Liver | Positive | Positive | (NEOPLASTIC NODULE, CARCINOMA) | Neoplastic Lesions |
| No | TR-162 | 95-80-7 | 2,4-Diaminotoluene (2,4-toluene diamine) | Rats | F344/N | Male | Dosed-Feed | Liver | Positive | Positive | (NEOPLASTIC NODULE, CARCINOMA) | Neoplastic Lesions |
| No | TR-162 | 95-80-7 | 2,4-Diaminotoluene (2,4-toluene diamine) | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (ADENOMA, CARCINOMA) | Neoplastic Lesions |
| No | TR-155 | 88-06-2 | 2,4,6-Trichlorophenol | Rats | F344/N | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| Yes | TR-155 | 88-06-2 | 2,4,6-Trichlorophenol | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Positive | Positive | (LEUKEMIA) | Neoplastic Lesions |
| No | TR-155 | 88-06-2 | 2,4,6-Trichlorophenol | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (ADENOMA, CARCINOMA) | Neoplastic Lesions |
| No | TR-155 | 88-06-2 | 2,4,6-Trichlorophenol | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Positive | Positive | (ADENOMA, CARCINOMA) | Neoplastic Lesions |
| No | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Mice | B6C3F1 | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| Yes | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Female | Dosed-Feed | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Male | Dosed-Feed | Skin | Positive | Positive | (BASAL CELL ADENOMA, SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Female | Dosed-Feed | Uterus/Cervix | Positive | Positive | (POLYP) | Neoplastic Lesions |
| No | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Female | Dosed-Feed | Zymbal Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/60 1/45 1/75 0/60; GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 1/45 0/75 0/60 | May Have Been Related |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 0/45 0/75 1/60; MENINGEAL SARCOMA 0/60 0/45 1/75 0/60 | May Have Been Related |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 9/45 32/75 17/59 OR CARCINOMA 0/60 5/45 11/75 18/59 COMBINED 0/60 14/45 42/75 32/59 | Neoplastic Lesions |
| Yes | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 1/60 3/45 6/75 4/60 | May Have Been Related |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 2/45 7/75 4/60 OR ADENOCARCINOMA 0/60 0/45 3/75 6/60 COMBINED 0/60 2/45 10/75 9/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 0/45 7/75 10/60 OR ADENOCARCINOMA 0/60 0/45 3/75 15/60 COMBINED 0/60 0/45 10/75 23/75 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 0/45 7/74 3/60 OR CARCINOMA 0/60 0/45 1/74 1/60 COMBINED 0/60 0/45 7/74 4/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 0/45 29/75 26/60 OR CARCINOMA 0/60 0/45 12/75 12/60 COMBINED 0/60 0/45 35/75 33/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 1/45 3/74 3/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 0/74 1/60 COMBINED 1/60 1/45 3/74 4/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 0/45 7/75 6/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 1/75 0/60 COMBINED 1/60 0/45 8/75 6/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/60 1/45 3/75 6/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 0/60 0/45 3/75 4/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 3/45 7/75 9/60 OR SQUAMOUS CELL CARCINOMA 0/60 1/45 2/75 4/60 COMBINED 0/60 3/45 9/75 13/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 2/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 1/75 3/60 COMBINED 0/60 0/45 4/75 5/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 2/60 4/45 4/75 8/60 OR CARCINOMA 0/60 0/45 2/75 1/60 COMBINED 2/60 4/45 6/75 9/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/60 3/45 5/75 5/60 OR BASAL CELL CARCINOMA 0/60 0/45 5/75 4/60 COMBINED 0/60 3/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA 0/60 1/45 6/75 5/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 4/75 7/60 COMBINED 0/60 3/45 9/75 12/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/60 10/45 52/75 29/60 OR BASAL CELL CARCINOMA 0/60 1/45 4/75 2/60 COMBINED 0/60 11/45 54/75 30/60; SEBACEOUS GLAND ADENOMA 0/60 0/45 7/75 5/60; KERATOACANTHOMA 1/60 1/45 8/75 5/60; SQUAMOUS CELL PAPILLOMA 0/60 0/45 8/75 15/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 10/75 13/60 COMBINED 0/60 2/45 17/75 27/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 4/45 11/75 12/60 OR CARCINOMA 0/60 2/45 22/75 35/60 COMBINED 0/57 6/45 32/75 42/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 1/60 1/45 13/75 16/60 OR CARCINOMA 0/60 2/45 21/75 23/60 COMBINED 1/60 3/45 32/75 36/60 | Neoplastic Lesions |
| No | TR-248 | 13552-44-8 | 4,4'-Methylenedianiline dihydrochloride | Mice | B6C3F1 | Male | Dosed-Water | Adrenal Gland Medulla | Positive | Positive | PHEOCHROMOCYTOMA 2/48 12/49 14/49 | Neoplastic Lesions |
| Yes | TR-248 | 13552-44-8 | 4,4'-Methylenedianiline dihydrochloride | Mice | B6C3F1 | Female | Dosed-Water | Hematopoietic System | Positive | Positive | LYMPHOMA 13/50 28/50 29/50 | Neoplastic Lesions |
| No | TR-248 | 13552-44-8 | 4,4'-Methylenedianiline dihydrochloride | Mice | B6C3F1 | Female | Dosed-Water | Liver | Positive | Positive | ADENOMA 3/50 9/50 12/50 | Neoplastic Lesions |
| No | TR-248 | 13552-44-8 | 4,4'-Methylenedianiline dihydrochloride | Mice | B6C3F1 | Male | Dosed-Water | Liver | Positive | Positive | CARCINOMA 10/49 33/50 29/50 | Neoplastic Lesions |
| No | TR-248 | 13552-44-8 | 4,4'-Methylenedianiline dihydrochloride | Rats | F344/N | Male | Dosed-Water | Liver | Positive | Positive | NEOPLASTIC NODULE 1/50 12/50 25/50 | Neoplastic Lesions |
| No | TR-248 | 13552-44-8 | 4,4'-Methylenedianiline dihydrochloride | Rats | F344/N | Female | Dosed-Water | Thyroid Gland C-Cell | Positive | Positive | ADENOMA 0/47 3/47 6/48 | Neoplastic Lesions |
| No | TR-248 | 13552-44-8 | 4,4'-Methylenedianiline dihydrochloride | Mice | B6C3F1 | Female | Dosed-Water | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA 0/50 1/47 13/50 | Neoplastic Lesions |
| No | TR-248 | 13552-44-8 | 4,4'-Methylenedianiline dihydrochloride | Mice | B6C3F1 | Male | Dosed-Water | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA 0/47 3/49 16/49 | Neoplastic Lesions |
| No | TR-248 | 13552-44-8 | 4,4'-Methylenedianiline dihydrochloride | Rats | F344/N | Female | Dosed-Water | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA 0/47 2/47 17/48 | Neoplastic Lesions |
| No | TR-248 | 13552-44-8 | 4,4'-Methylenedianiline dihydrochloride | Rats | F344/N | Male | Dosed-Water | Thyroid Gland Follicular Cell | Positive | Positive | CARCINOMA 0/49 0/47 7/48 | Neoplastic Lesions |
| No | TR-042 | 320-67-2 | 5-Azacytidine | Mice | B6C3F1 | Male | Intraperitoneal Injection | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| No | TR-042 | 320-67-2 | 5-Azacytidine | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| No | TR-042 | 320-67-2 | 5-Azacytidine | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| Yes | TR-042 | 320-67-2 | 5-Azacytidine | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR GRANULOCYTIC SARCOMA) | Neoplastic Lesions |
| No | TR-253 | 2835-39-4 | Allyl isovalerate | Mice | B6C3F1 | Male | Gavage | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-253 | 2835-39-4 | Allyl isovalerate | Rats | F344/N | Female | Gavage | Unspecified | Negative | Not applicable | Not applicable | |
| Yes | TR-253 | 2835-39-4 | Allyl isovalerate | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Positive | Positive | LYMPHOMA 11/50 11/50 18/50 | Neoplastic Lesions |
| Yes | TR-253 | 2835-39-4 | Allyl isovalerate | Rats | F344/N | Male | Gavage | Hematopoietic System | Positive | Positive | LEUKEMIA 1/50 4/50 7/50 | Neoplastic Lesions |
| Yes | TR-543 | 98-83-9 | alpha-Methylstyrene | Rats | F344/N | Male | Inhalation | Hematopoietic System | Some Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 26/50 32/50 29/50 38/50 | May Have Been Related |
| No | TR-543 | 98-83-9 | alpha-Methylstyrene | Rats | F344/N | Male | Inhalation | Kidney Tubular Cell | Some Evidence | Some Evidence | ADENOMA (STANDARD EVALUATION) 0/50 0/50 1/50 0/50 (STANDARD AND EXTENDED EVALUATIONS COMBINED) 1/50 2/50 2/50 5/50 ADENOMA OR CARCINOMA (STANDARD EVALUATION) 0/50 0/50 2/50 2/50 (STANDARD AND EXTENDED EVALUATIONS COMBINED) 1/50 2/50 3/50 7/50 | Neoplastic Lesions |
| No | TR-543 | 98-83-9 | alpha-Methylstyrene | Mice | B6C3F1/N | Male | Inhalation | Liver | Equivocal Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 28/50 36/50 33/50 37/50 | May Have Been Related |
| No | TR-543 | 98-83-9 | alpha-Methylstyrene | Mice | B6C3F1/N | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 10/50 20/50 21/50 23/50 CARCINOMA 3/50 9/50 6/50 18/50 ADENOMA OR CARCINOMA 13/50 26/50 24/50 33/50 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 0/49 9/46 13/49 11/48 | Neoplastic Lesions |
| Yes | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 15/49 25/45 26/50 22/49 | Neoplastic Lesions |
| Yes | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 4/49 10/48 10/50 15/49 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 4/49 2/42 5/50 9/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 3/42 6/50 6/49 COMBINED 4/49 5/42 10/50 13/49 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 6/49 6/48 8/50 12/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 5/49 11/48 12/50 14/49 COMBINED 10/49 16/48 19/50 21/49 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/49 2/45 5/50 10/49; CARCINOSARCOMA 0/49 0/45 1/50 4/49 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 4/50 8/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 1/50 4/50 5/50 COMBINED 1/50 5/50 12/50 9/50 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Male | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 6/50 11/50 13/50 OR SQUAMOUS CELL CARCINOMA 0/50 3/50 5/50 7/50 COMBINED 1/50 9/50 16/50 19/50 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Ovary | Clear Evidence | Clear Evidence | BENIGN MIXED TUMORS 0/47 1/44 12/49 7/48; GRANULOSA CELL TUMOR 1/47 1/44 6/49 7/48 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Preputial Gland | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/21 3/28 18/29 28/35 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/50 1/50 5/50; SQUAMOUS CELL CARCINOMA 0/50 5/50 3/50 8/50 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/43 0/32 1/37 3/31 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/43 1/34 4/40 21/39 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Female | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/45 5/40 5/44 14/46 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 2/32 6/46 10/42 | Neoplastic Lesions |
| Yes | TR-533 | 119-61-9 | Benzophenone | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Some Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 27/50 41/50 39/50 24/50 | May Have Been Related |
| No | TR-533 | 119-61-9 | Benzophenone | Rats | F344/N | Female | Dosed-Feed | Hematopoietic System | Equivocal Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 19/50 25/50 30/50 29/50; HISTIOCYTIC SARCOMA 0/50 0/50 1/50 2/50 | Neoplastic Lesions |
| Yes | TR-533 | 119-61-9 | Benzophenone | Mice | B6C3F1/N | Female | Dosed-Feed | Hematopoietic System | Some Evidence | Some Evidence | HISTIOCYTIC SARCOMA: 0/50 0/50 5/50 3/50 | Neoplastic Lesions |
| No | TR-533 | 119-61-9 | Benzophenone | Rats | F344/N | Male | Dosed-Feed | Kidney Tubular Cell | Some Evidence | Some Evidence | ADENOMA (STANDARD EVALUATION) 1/50 1/50 2/50 4/50 (STANDARD AND EXTENDED EVALUATIONS COMBINED) 2/50 2/50 7/50 8/50 | Neoplastic Lesions |
| No | TR-533 | 119-61-9 | Benzophenone | Mice | B6C3F1/N | Female | Dosed-Feed | Liver | Some Evidence | Equivocal Evidence | ADENOMA 5/50 4/50 10/50 8/50 | May Have Been Related |
| No | TR-533 | 119-61-9 | Benzophenone | Mice | B6C3F1/N | Male | Dosed-Feed | Liver | Some Evidence | Some Evidence | ADENOMA 11/50 15/50 23/50 23/50 ADENOMA, CARCINOMA, OR HEPATOBLASTOMA 18/50 20/50 25/50 29/50 | Neoplastic Lesions |
| No | TR-213 | 85-68-7 | Butyl benzyl phthalate | Rats | F344/N | Male | Dosed-Feed | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| No | TR-213 | 85-68-7 | Butyl benzyl phthalate | Mice | B6C3F1 | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-213 | 85-68-7 | Butyl benzyl phthalate | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| Yes | TR-213 | 85-68-7 | Butyl benzyl phthalate | Rats | F344/N | Female | Dosed-Feed | Hematopoietic System | Positive | Positive | LEUKEMIA 7/49 7/49 18/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Adrenal Gland Medulla | Clear Evidence | Equivocal Evidence | PHEOCHROMOCYTOMA 1/50 3/35 5/64 1/50 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Adrenal Gland Medulla | Clear Evidence | Equivocal Evidence | PHEOCHROMOCYTOMA 16/50 11/35 24/63 19/49 OR MALIGNANT PHEOCHROMOCYTOMA 2/50 0/35 3/63 2/49 COMBINED 17/50 11/35 27/63 21/49 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 7/48 10/32 10/62 10/50, CARCINOMA 4/48 9/32 19/62 15/50, COMBINED 11/48 17/32 28/62 23/50 | Neoplastic Lesions |
| Yes | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 12/50 13/35 18/65 5/50 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 1/35 0/65 3/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 0/35 1/65 2/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 0/35 15/64 6/50, CARCINOMA 0/50 0/35 6/64 3/50, COMBINED 0/50 0/35 19/64 8/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 2/50 1/35 10/65 15/50, CARCINOMA 0/50 1/35 6/65 7/50, COMBINED 2/50 2/35 15/65 20/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Lung | Clear Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 2/35 1/65 3/50, ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 2/50 2/35 2/65 3/50 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 2/35 8/65 4/50, ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 1/50 2/35 9/65 4/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Equivocal Evidence | ADENOCARCINOMA 0/50 3/35 6/65 3/50 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/35 1/65 2/50 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/35 6/65 4/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 3/65 2/50, COMBINED 0/50 3/35 9/65 6/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/50 3/35 5/65 3/50, BASAL CELL CARCINOMA 0/50 1/35 2/65 2/50, COMBINED 0/50 4/35 7/65 5/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 1/50 4/35 26/65 30/50, BASAL CELL CARCINOMA 0/50 1/35 5/65 6/50, COMBINED 1/50 5/35 28/65 32/50; KERATOACANTHOMA 1/50 1/35 4/65 7/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 5/65 5/50, SEBACEOUS GLAND CARCINOMA 1/50 0/35 0/65 1/50, COMBINED 1/50 1/35 5/65 6/50; SQUAMOUS CELL PAPILLOMA 1/50 0/35 3/65 2/50, SQUAMOUS CELL CARCINOMA 0/50 2/35 8/65 7/50, COMBINED 1/50 2/35 11/65 9/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/35 2/65 6/50, CARCINOMA 0/50 3/35 17/65 13/50, COMBINED 0/50 3/35 18/65 19/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/35 1/65 1/50, CARCINOMA 0/50 0/35 7/65 6/50, COMBINED 0/50 0/35 8/65 7/50 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Mice | B6C3F1 | Female | Dosed-Feed | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | PHEOCHROMOCYTOMA 1/48 7/47 7/45 OR MALIGNANT PHEOCHROMOCYTOMA 0/48 1/47 1/45 COMBINED 1/48 8/47 8/45 | Neoplastic Lesions |
| Yes | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Clear Evidence | Equivocal Evidence | LYMPHOMA 17/50 24/50 25/50 | May Have Been Related |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | CARCINOMA 3/49 19/50 37/49 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | CARCINOMA 10/50 20/50 27/50 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | CARCINOMA 0/50 2/50 8/50 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Equivocal Evidence | ADENOMA 0/50 3/50 1/50, FIBROADENOMA 22/50 31/50 29/50, OR ADENOCARCINOMA 2/50 2/50 5/50 COMBINED 23/50 32/50 32/50 | May Have Been Related |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | TRICHOEPITHELIOMA 0/50 0/50 7/50; SEBACEOUS ADENOMA 0/50 0/50 5/50; SQUAMOUS CELL CARCINOMA 0/50 1/50 10/50 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Female | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | FIBROMA 0/50 15/50 10/50 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | FIBROMA 2/50 20/50 16/50 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/47 0/48 4/50 OR CARCINOMA 0/47 2/48 2/50 COMBINED 0/47 2/48 6/50 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/49 0/46 9/44 OR CARCINOMA 0/49 5/46 18/44 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Female | Dosed-Feed | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/50 2/50 7/50 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 1/50 1/50 13/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/50 1/35 1/65 2/50 | May Have Been Related |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/50 5/31 12/64 12/50, CARCINOMA 2/50 6/31 12/64 15/50, COMBINED 7/50 11/31 24/64 27/50 | Neoplastic Lesions |
| Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 17/50 19/35 28/65 20/50 | May Have Been Related |
| Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 7/50 13/35 27/65 15/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/50 0/35 3/65 1/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 1/35 6/65 8/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 0/35 1/65 3/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 1/35 0/65 2/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 0/35 2/65 4/50, CARCINOMA 0/50 0/35 0/65 1/50, COMBINED 0/50 0/35 2/65 5/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 6/35 8/65 7/50, CARCINOMA 0/50 0/35 1/65 4/50, COMBINED 0/50 6/35 9/65 11/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/50 3/35 12/65 9/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 8/65 6/50, COMBINED 2/50 4/35 19/65 15/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 9/35 18/65 15/50, SQUAMOUS CELL CARCINOMA 1/50 1/35 6/65 2/50, COMBINED 1/50 10/35 24/65 17/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 6/49 2/35 12/64 8/48, CARCINOMA 2/49 3/35 11/64 1/48, COMBINED 8/49 5/35 23/64 9/48 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/35 5/65 5/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 0/50 2/35 6/65 5/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 2/50 8/35 23/65 26/50, BASAL CELL CARCINOMA 0/50 2/35 4/65 10/50, COMBINED 2/50 9/35 27/65 28/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 7/65 3/50; SQUAMOUS CELL PAPILLOMA 2/50 3/35 5/65 8/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 7/65 13/50, COMBINED 2/50 4/35 11/65 19/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/35 1/65 1/50, ADENOCARCINOMA 1/50 0/35 0/65 3/50, COMBINED 1/50 0/35 1/65 4/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/35 5/65 3/50, CARCINOMA 0/50 4/35 7/65 14/50, COMBINED 0/50 4/35 11/65 17/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/35 2/65 4/50, CARCINOMA 1/50 3/35 8/65 17/50, COMBINED 1/50 5/35 10/65 20/50 | Neoplastic Lesions |
| No | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Rats | F344/N | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Rats | F344/N | Male | Dosed-Feed | Forestomach | Positive | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/49 1/50 0/50; FIBROSARCOMA 0/49 1/50 0/50; SARCOMA 0/49 0/50 1/50 | May Have Been Related |
| No | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Rats | F344/N | Male | Dosed-Feed | Glandular Stomach | Positive | Equivocal Evidence | ADENOMA 0/49 1/50 0/50; ADENOCARCINOMA 0/49 1/501/50; SARCOMA 0/49 0/50 1/50 | May Have Been Related |
| Yes | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Positive | Equivocal Evidence | LYMPHOMA 10/50 16/50 19/50 | May Have Been Related |
| No | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | ADENOMA 0/50 6/50 12/50 | Neoplastic Lesions |
| No | TR-222 | 2832-40-8 | C.I. Disperse Yellow 3 | Rats | F344/N | Male | Dosed-Feed | Liver | Positive | Positive | NEOPLASTIC NODULE 1/49 15/50 10/50 | Neoplastic Lesions |
| No | TR-134 | 128-66-5 | C.I. Vat Yellow 4 | Mice | B6C3F1 | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-134 | 128-66-5 | C.I. Vat Yellow 4 | Rats | F344/N | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-134 | 128-66-5 | C.I. Vat Yellow 4 | Rats | F344/N | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| Yes | TR-134 | 128-66-5 | C.I. Vat Yellow 4 | Mice | B6C3F1 | Male | Dosed-Feed | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| Yes | TR-308 | 108171-26-2 | Chlorinated paraffins: C12, 60% chlorine | Rats | F344/N | Male | Gavage | Hematopoietic System | Clear Evidence | Equivocal Evidence | LEUKEMIA 7/50 12/50 14/50 | May Have Been Related |
| No | TR-308 | 108171-26-2 | Chlorinated paraffins: C12, 60% chlorine | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 7/50 3/49 ADENOCARCINOMA 0/50 2/50 0/49 COMBINED 0/50 9/50 3/49 | Neoplastic Lesions |
| No | TR-308 | 108171-26-2 | Chlorinated paraffins: C12, 60% chlorine | Mice | B6C3F1 | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 0/50 18/50 22/50 OR CARCINOMA 3/50 4/50 9/50 COMBINED 3/50 22/50 28/50 | Neoplastic Lesions |
| No | TR-308 | 108171-26-2 | Chlorinated paraffins: C12, 60% chlorine | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 11/50 20/50 29/50 OR CARCINOMA 11/50 15/50 17/50 COMBINED 2/50 34/50 38/50 | Neoplastic Lesions |
| No | TR-308 | 108171-26-2 | Chlorinated paraffins: C12, 60% chlorine | Rats | F344/N | Female | Gavage | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 4/50 7/50; CARCINOMA 0/50 1/50 1/50 | Neoplastic Lesions |
| No | TR-308 | 108171-26-2 | Chlorinated paraffins: C12, 60% chlorine | Rats | F344/N | Male | Gavage | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 10/50 16/48; CARCINOMA 0/50 3/50 2/48 | Neoplastic Lesions |
| No | TR-308 | 108171-26-2 | Chlorinated paraffins: C12, 60% chlorine | Mice | B6C3F1 | Female | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 8/50 12/49 18/49 OR CARCINOMA 0/50 0/49 2/49 COMBINED 8/50 12/49 15/49 | Neoplastic Lesions |
| No | TR-308 | 108171-26-2 | Chlorinated paraffins: C12, 60% chlorine | Rats | F344/N | Female | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 6/50 3/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 6/50 6/50 | Neoplastic Lesions |
| No | TR-305 | 108171-27-3 | Chlorinated paraffins: C23, 43% chlorine | Rats | F344/N | Male | Gavage | Unspecified | No Evidence | Not applicable | Not applicable | |
| No | TR-305 | 108171-27-3 | Chlorinated paraffins: C23, 43% chlorine | Rats | F344/N | Female | Gavage | Adrenal Gland Medulla | Equivocal Evidence | Equivocal Evidence | PHEOCHROMOCYTOMA 1/50 4/50 6/50 7/50 | Neoplastic Lesions |
| Yes | TR-305 | 108171-27-3 | Chlorinated paraffins: C23, 43% chlorine | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 6/50 12/50 16/50 | Neoplastic Lesions |
| No | TR-305 | 108171-27-3 | Chlorinated paraffins: C23, 43% chlorine | Mice | B6C3F1 | Female | Gavage | Liver | Equivocal Evidence | Equivocal Evidence | ADENOMA 3/50 2/49 7/50 OR CARCINOMA 1/50 1/49 6/50 COMBINED 4/50 3/49 10/50 | Neoplastic Lesions |
| No | TR-342 | 62-73-7 | Dichlorvos | Mice | B6C3F1 | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 5/49 6/49 18/50 | Neoplastic Lesions |
| No | TR-342 | 62-73-7 | Dichlorvos | Mice | B6C3F1 | Male | Gavage | Forestomach | Some Evidence | Some Evidence | SQUAMOUS CELL PAPILLOMA 1/50 1/50 5/50 | Neoplastic Lesions |
| Yes | TR-342 | 62-73-7 | Dichlorvos | Rats | F344/N | Male | Gavage | Hematopoietic System | Some Evidence | Some Evidence | LEUKEMIA 11/50 20/50 21/50 | Neoplastic Lesions |
| No | TR-342 | 62-73-7 | Dichlorvos | Rats | F344/N | Female | Gavage | Mammary Gland | Equivocal Evidence | Equivocal Evidence | FIBROADENOMA 9/50 19/50 16/50 OR ADENOMA 0/50 0/50 1/50 COMBINED 9/50 19/50 17/50 | Neoplastic Lesions |
| No | TR-342 | 62-73-7 | Dichlorvos | Rats | F344/N | Female | Gavage | Pancreas Acinar Cell | Equivocal Evidence | Equivocal Evidence | ADENOMA 2/50 3/47 6/50 | Neoplastic Lesions |
| No | TR-342 | 62-73-7 | Dichlorvos | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Some Evidence | Some Evidence | ADENOMA 25/50 30/49 33/50 | Neoplastic Lesions |
| No | TR-323 | 756-79-6 | Dimethyl methylphosphonate | Mice | B6C3F1 | Male | Gavage | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| No | TR-323 | 756-79-6 | Dimethyl methylphosphonate | Mice | B6C3F1 | Female | Gavage | Unspecified | No Evidence | Not applicable | Not applicable | |
| No | TR-323 | 756-79-6 | Dimethyl methylphosphonate | Rats | F344/N | Female | Gavage | Unspecified | No Evidence | Not applicable | Not applicable | |
| Yes | TR-323 | 756-79-6 | Dimethyl methylphosphonate | Rats | F344/N | Male | Gavage | Hematopoietic System | Some Evidence | Equivocal Evidence | LEUKEMIA 10/50 11/50 17/50 | May Have Been Related |
| No | TR-323 | 756-79-6 | Dimethyl methylphosphonate | Rats | F344/N | Male | Gavage | Kidney Transitional Cell | Some Evidence | Some Evidence | PAPILLOMA 0/50 7/50 3/49 | Neoplastic Lesions |
| No | TR-323 | 756-79-6 | Dimethyl methylphosphonate | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Some Evidence | Some Evidence | ADENOCARCINOMA 0/50 2/50 3/49 | Neoplastic Lesions |
| No | TR-298 | 597-25-1 | Dimethyl morpholinophosphoramidate | Mice | B6C3F1 | Female | Gavage | Unspecified | No Evidence | Not applicable | Not applicable | |
| No | TR-298 | 597-25-1 | Dimethyl morpholinophosphoramidate | Mice | B6C3F1 | Male | Gavage | Unspecified | No Evidence | Not applicable | Not applicable | |
| Yes | TR-298 | 597-25-1 | Dimethyl morpholinophosphoramidate | Rats | F344/N | Female | Gavage | Hematopoietic System | Some Evidence | Some Evidence | LEUKEMIA 9/50 13/50 12/49 18/50 | Neoplastic Lesions |
| Yes | TR-298 | 597-25-1 | Dimethyl morpholinophosphoramidate | Rats | F344/N | Male | Gavage | Hematopoietic System | Some Evidence | Some Evidence | LEUKEMIA 14/50 21/50 19/50 25/50 | Neoplastic Lesions |
| Yes | TR-512 | 37319-17-8 | Elmiron (sodium pentosanpolysulfate) | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Some Evidence | Equivocal Evidence | MALIGNANT LYMPHOMA (ALL ORGANS) 7/50 8/50 6/50 16/50 | May Have Been Related |
| No | TR-512 | 37319-17-8 | Elmiron (sodium pentosanpolysulfate) | Mice | B6C3F1 | Male | Gavage | Liver | Some Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 23/50 23/50 26/50 31/50 | May Have Been Related |
| No | TR-512 | 37319-17-8 | Elmiron (sodium pentosanpolysulfate) | Mice | B6C3F1 | Female | Gavage | Liver | Some Evidence | Some Evidence | HEMANGIOSARCOMA 1/50 1/49 1/50 4/49; ADENOMA 7/50 5/49 4/50 15/49; HEPATOCELLULAR ADENOMA OR CARCINOMA 10/50 8/49 9/50 18/49 | Neoplastic Lesions |
| No | TR-512 | 37319-17-8 | Elmiron (sodium pentosanpolysulfate) | Mice | B6C3F1 | Male | Gavage | Liver | Some Evidence | Some Evidence | HEMANGIOSARCOMA 2/50 0/50 4/50 9/50 | Neoplastic Lesions |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Rats | Sprague Dawley | Female | Gavage | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Rats | Sprague Dawley | Male | Gavage | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Female | Gavage | Forestomach | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Male | Gavage | Forestomach | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Female | Gavage | Heart | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Male | Gavage | Heart | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| Yes | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| Yes | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Female | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Male | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA) | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | CYSTADENOMA 1/46 6/46 8/47 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | CYSTADENOMA 1/43 9/44 8/42 | Neoplastic Lesions |
| Yes | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 9/49 6/48 22/49 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 2/49 4/48 17/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 1/48 7/49 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 11/50 11/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 6/50 10/50 16/50 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/49 6/48 4/49; ADENOSQUAMOUS CARCINOMA 0/49 2/48 2/49 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/49 1/47 5/49 | Neoplastic Lesions |
| No | TR-402 | 110-00-9 | Furan | Mice | B6C3F1 | Female | Gavage | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | PHEOCHROMOCYTOMA 2/50 1/50 6/50 | Neoplastic Lesions |
| No | TR-402 | 110-00-9 | Furan | Mice | B6C3F1 | Male | Gavage | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | PHEOCHROMOCYTOMA 1/49 6/50 10/50 | Neoplastic Lesions |
| Yes | TR-402 | 110-00-9 | Furan | Rats | F344/N | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 8/50 9/50 17/50 21/50 | Neoplastic Lesions |
| Yes | TR-402 | 110-00-9 | Furan | Rats | F344/N | Male | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 8/50 11/50 17/50 25/50 | Neoplastic Lesions |
| No | TR-402 | 110-00-9 | Furan | Mice | B6C3F1 | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 5/50 31/50 48/50, CARCINOMA 2/50 7/50 27/50, COMBINED 7/50 34/50 50/50 | Neoplastic Lesions |
| No | TR-402 | 110-00-9 | Furan | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 20/50 33/50 42/50, CARCINOMA 7/50 32/50 34/50, COMBINED 26/50 44/50 50/50 | Neoplastic Lesions |
| No | TR-402 | 110-00-9 | Furan | Rats | F344/N | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 4/50 7/50, CARCINOMA 0/50 0/50 0/50 1/50, COMBINED 0/50 2/50 4/50 8/50; CHOLANGIOCARCINOMA 0/50 49/50 50/50 48/50 | Neoplastic Lesions |
| No | TR-402 | 110-00-9 | Furan | Rats | F344/N | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 1/50 4/50 18/50 27/50, CARCINOMA 0/50 1/50 6/50 18/50, COMBINED 1/50 5/50 22/50 35/50; CHOLANGIOCARCINOMA 0/50 43/50 48/50 49/50 | Neoplastic Lesions |
| No | TR-492 | 1303-00-0 | Gallium arsenide | Rats | F344/N | Female | Inhalation | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | BENIGN PHEOCHROMOCYTOMA 4/50 5/49 6/50 13/49 | Neoplastic Lesions |
| Yes | TR-492 | 1303-00-0 | Gallium arsenide | Rats | F344/N | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 22/50 21/50 18/50 33/50 | Neoplastic Lesions |
| No | TR-492 | 1303-00-0 | Gallium arsenide | Rats | F344/N | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 0/50 2/50 7/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/50 2/50 3/50 COMBINED 0/50 0/50 4/50 9/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 4/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 5/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Epididymis | Clear Evidence | Equivocal Evidence | SARCOMA 0/50 0/50 2/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Glandular Stomach | Clear Evidence | Equivocal Evidence | FIBROSARCOMA 0/50 0/50 2/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LEUKEMIA 13/50 14/50 20/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 3/50 8/50 7/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 3/50 34/50 39/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Urinary Bladder | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 1/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 1/50 3/50 6/50 | Neoplastic Lesions |
| Yes | TR-366 | 123-31-9 | Hydroquinone | Rats | F344/N | Female | Gavage | Hematopoietic System | Some Evidence | Some Evidence | Leukemia 9/55 15/55 22/55 | Neoplastic Lesions |
| No | TR-366 | 123-31-9 | Hydroquinone | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Some Evidence | Some Evidence | Adenoma 0/55 4/55 8/55 | Neoplastic Lesions |
| No | TR-366 | 123-31-9 | Hydroquinone | Mice | B6C3F1 | Female | Gavage | Liver | Some Evidence | Some Evidence | Adenoma 2/55 15/55 12/55; adenoma or carcinoma (combined) 3/55 16/55 13/55 | Neoplastic Lesions |
| No | TR-078 | 21416-87-5 | ICRF-159 | Mice | B6C3F1 | Male | Intraperitoneal Injection | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-078 | 21416-87-5 | ICRF-159 | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Unspecified | Negative | Not applicable | Not applicable | |
| Yes | TR-078 | 21416-87-5 | ICRF-159 | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| No | TR-078 | 21416-87-5 | ICRF-159 | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Uterus/Cervix | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Female | Inhalation | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | BENIGN PHEOCHROMOCYTOMA 2/50 6/48 2/50 9/49 | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Male | Inhalation | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | BENIGN PHEOCHROMOCYTOMA 10/50 22/50 16/49 23/50 BENIGN OR MALIGNANT PHEOCHROMOCYTOMA 10/50 26/50 18/49 24/50 | Neoplastic Lesions |
| Yes | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Female | Inhalation | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 14/50 21/50 14/50 24/50 | May Have Been Related |
| Yes | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Male | Inhalation | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 16/50 23/50 29/50 25/50 | May Have Been Related |
| No | TR-499 | 22398-80-7 | Indium phosphide | Mice | B6C3F1 | Male | Inhalation | Intestines (Large) | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 5/50 3/50; ADEMONA OR CARCINOMA 1/50 2/50 6/50 3/50 | May Have Been Related |
| No | TR-499 | 22398-80-7 | Indium phosphide | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 12/50 14/50 18/50 14/50; CARCINOMA 6/50 17/50 8/50 10/50; COMBINED 18/50 28/50 24/50 23/50 | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Mice | B6C3F1 | Male | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 17/50 24/50 23/50 32/50; CARCINOMA 11/50 22/50 23/50 16/50; COMBINED 26/50 40/50 37/50 39/50 | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADEMONA 3/50 6/50 10/50 7/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 6/50 5/50 7/50; COMBINED 4/50 11/50 15/50 14/50 | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR CARCINOMA 6/50 15/50 22/50 13/50 | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADEMONA 0/50 7/50 5/50 19/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 3/50 1/50 11/50; COMBINED 1/50 10/50 6/50 26/50 | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADEMONA 6/50 13/50 27/50 30/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 10/50 8/50 16/50; COMBINED 7/50 22/50 30/50 35/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Female | Inhalation | Mammary Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 8/50 3/50 2/50 | May Have Been Related |
| No | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Male | Inhalation | Skin | Clear Evidence | Equivocal Evidence | FIBROMA 1/50 4/50 7/50 3/50; FIBROMA OR FIBROSARCOMA 2/50 4/50 8/50 4/50 | May Have Been Related |
| No | TR-340 | 5634-39-9 | Iodinated glycerol | Mice | B6C3F1 | Female | Gavage | Forestomach | Some Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 1/49 2/50 5/49 | May Have Been Related |
| No | TR-340 | 5634-39-9 | Iodinated glycerol | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Some Evidence | Some Evidence | ADENOMA 6/50 8/40 13/50 OR CARCINOMA 0/50 0/40 1/50 COMBINED 6/50 8/40 14/50 | Neoplastic Lesions |
| Yes | TR-340 | 5634-39-9 | Iodinated glycerol | Rats | F344/N | Male | Gavage | Hematopoietic System | Some Evidence | Some Evidence | LEUKEMIA 14/50 29/50 24/50 | Neoplastic Lesions |
| No | TR-340 | 5634-39-9 | Iodinated glycerol | Rats | F344/N | Male | Gavage | Nasal Cavity | Some Evidence | Equivocal Evidence | ADENOMA 0/48 0/47 2/49 | May Have Been Related |
| No | TR-340 | 5634-39-9 | Iodinated glycerol | Mice | B6C3F1 | Female | Gavage | Pituitary Gland | Some Evidence | Some Evidence | ADENOMA 10/47 15/45 24/46 | Neoplastic Lesions |
| No | TR-340 | 5634-39-9 | Iodinated glycerol | Rats | F344/N | Male | Gavage | Thyroid Gland Follicular Cell | Some Evidence | Some Evidence | CARCINOMA 0/49 5/49 1/49 | Neoplastic Lesions |
| No | TR-032 | 3778-73-2 | Isophosphamide | Mice | B6C3F1 | Male | Intraperitoneal Injection | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-032 | 3778-73-2 | Isophosphamide | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Unspecified | Negative | Not applicable | Not applicable | |
| Yes | TR-032 | 3778-73-2 | Isophosphamide | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| No | TR-032 | 3778-73-2 | Isophosphamide | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (FIBROADENOMA) | Neoplastic Lesions |
| No | TR-032 | 3778-73-2 | Isophosphamide | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Uterus/Cervix | Positive | Positive | (LEIOMYOSARCOMA) | Neoplastic Lesions |
| Yes | TR-039 | 303-34-4 | Lasiocarpine | Rats | F344/N | Female | Dosed-Feed | Hematopoietic System | Positive | Positive | Lymphoma/Leukemia | Neoplastic Lesions |
| No | TR-039 | 303-34-4 | Lasiocarpine | Rats | F344/N | Female | Dosed-Feed | Liver | Positive | Positive | Angiosarcoma, carcinoma, adenoma | Neoplastic Lesions |
| No | TR-039 | 303-34-4 | Lasiocarpine | Rats | F344/N | Male | Dosed-Feed | Liver | Positive | Positive | Angiosarcoma, carcinoma, adenoma | Neoplastic Lesions |
| Yes | TR-538 | 108-10-1 | Methyl isobutyl ketone | Rats | F344/N | Male | Inhalation | Hematopoietic System | Some Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 25/50 26/50 32/50 35/50 | May Have Been Related |
| No | TR-538 | 108-10-1 | Methyl isobutyl ketone | Rats | F344/N | Female | Inhalation | Kidney Mesenchymal Cell | Equivocal Evidence | Equivocal Evidence | TUMOR MALIGNANT 0/50 0/50 0/50 2/50 | Neoplastic Lesions |
| No | TR-538 | 108-10-1 | Methyl isobutyl ketone | Rats | F344/N | Male | Inhalation | Kidney Tubular Cell | Some Evidence | Some Evidence | ADENOMA (STANDARD EVALUATION - 0/50 0/50 2/50 3/50; STANDARD AND EXTENDED EVAULATION COMBINED - 2/50 3/50 3/50 10/50); CARCINOMA (STANDARD EVALUATION - 0/50 1/50 0/50 2/50); ADENOMA OR CARCINOMA (COMBINED) (STANDARD EVAULATION - 0/50 1/50 2/50 4/50; STANDARD AND EXTENDED EVALUATION - 2/50 4/50 3/50 11/50) | Neoplastic Lesions |
| No | TR-538 | 108-10-1 | Methyl isobutyl ketone | Mice | B6C3F1 | Female | Inhalation | Liver | Some Evidence | Some Evidence | ADENOMA 13/50 15/50 20/50 23/50 ADENOMA OR CARCINOMA (COMBINED) 17/50 17/50 22/50 27/50 | Neoplastic Lesions |
| No | TR-538 | 108-10-1 | Methyl isobutyl ketone | Mice | B6C3F1 | Male | Inhalation | Liver | Some Evidence | Some Evidence | ADENOMA 17/50 25/50 23/50 34/50 ADENOMA OR CARCINOMA (COMBINED) 27/50 34/50 28/50 37/50 | Neoplastic Lesions |
| No | TR-540 | 7220-79-3 | Methylene blue trihydrate | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Equivocal Evidence | Equivocal Evidence | MALIGNANT LYMPHOMA 6/50 4/50 9/50 12/50 | May Have Been Related |
| Yes | TR-540 | 7220-79-3 | Methylene blue trihydrate | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Some Evidence | Equivocal Evidence | MALIGNANT LYMPHOMA 2/50 2/50 2/50 5/50 | May Have Been Related |
| No | TR-540 | 7220-79-3 | Methylene blue trihydrate | Mice | B6C3F1 | Male | Gavage | Intestines (Small) | Some Evidence | Some Evidence | CARCINOMA 0/50 1/50 2/50 4/50 ADENOMA OR CARCINOMA 1/50 2/50 4/50 6/50 | Neoplastic Lesions |
| No | TR-540 | 7220-79-3 | Methylene blue trihydrate | Rats | F344/N | Male | Gavage | Pancreas Islet Cell | Some Evidence | Some Evidence | ADENOMA 4/50 9/50 12/50 8/50 ADENOMA OR CARCINOMA 4/50 9/50 14/50 8/50 | Neoplastic Lesions |
| No | TR-313 | 2385-85-5 | Mirex | Rats | F344/N | Male | Dosed-Feed | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | PHEOCHROMOCYTOMA 8/51 7/52 13/52 11/52 18/51 19/51 | Neoplastic Lesions |
| Yes | TR-313 | 2385-85-5 | Mirex | Rats | F344/N | Female | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | LEUKEMIA 6/52 9/52 14/52 | Neoplastic Lesions |
| No | TR-313 | 2385-85-5 | Mirex | Rats | F344/N | Male | Dosed-Feed | Kidney Transitional Cell | Clear Evidence | Clear Evidence | PAPILLOMA 0/51 0/51 0/52 0/52 1/51 3/52 | Neoplastic Lesions |
| No | TR-313 | 2385-85-5 | Mirex | Rats | F344/N | Female | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 2/52 23/52 30/52 | Neoplastic Lesions |
| No | TR-313 | 2385-85-5 | Mirex | Rats | F344/N | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 3/52 5/52 5/52 14/52 15/52 26/52 | Neoplastic Lesions |
| No | TR-416 | 91-23-6 | o-Nitroanisole | Rats | F344/N | Female | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 0/50 1/50 | May Have Been Related |
| No | TR-416 | 91-23-6 | o-Nitroanisole | Rats | F344/N | Male | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA O/50 0/50 1/50 1/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 1/50 | May Have Been Related |
| Yes | TR-416 | 91-23-6 | o-Nitroanisole | Rats | F344/N | Female | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 14/50 11/50 14/50 26/50 | Neoplastic Lesions |
| Yes | TR-416 | 91-23-6 | o-Nitroanisole | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 26/50 25/50 42/50 34/50 | Neoplastic Lesions |
| No | TR-416 | 91-23-6 | o-Nitroanisole | Rats | F344/N | Female | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | (STOP STUDY) ADENOMATOUS POLYP 0/60 8/60 18/60, CARCINOMA 0/60 0/60 2/60 | Neoplastic Lesions |
| No | TR-416 | 91-23-6 | o-Nitroanisole | Rats | F344/N | Male | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | (STOP STUDY) ADENOMATOUS POLYP 0/60 26/60 30/60, CARCINOMA 0/60 0/60 5/60 | Neoplastic Lesions |
| No | TR-416 | 91-23-6 | o-Nitroanisole | Rats | F344/N | Female | Dosed-Feed | Kidney Transitional Cell | Clear Evidence | Clear Evidence | (STOP STUDY) PAPILLOMA 0/60 0/60 1/60 OR CARCINOMA 0/60 0/60 1/60 | Neoplastic Lesions |
| No | TR-416 | 91-23-6 | o-Nitroanisole | Rats | F344/N | Male | Dosed-Feed | Kidney Transitional Cell | Clear Evidence | Clear Evidence | PAPILLOMA (STOP STUDY) 0/60 0/60 4/60 OR CARCINOMA 0/60 1/60 8/60 | Neoplastic Lesions |
| No | TR-416 | 91-23-6 | o-Nitroanisole | Rats | F344/N | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/49 1/50 1/50 1/49 OR CARCINOMA 0/49 0/50 0/50 2/49 | May Have Been Related |
| No | TR-416 | 91-23-6 | o-Nitroanisole | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | ADENOMA 14/50 26/50 41/50 29/50; CARCINOMA 7/50 12/50 11/50 7/50; HEPATOBLASTOMA 0/50 3/50 17/50 9/50 | Neoplastic Lesions |
| No | TR-416 | 91-23-6 | o-Nitroanisole | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Some Evidence | Some Evidence | ADENOMA 14/50 2/50 36/50 18/50 | Neoplastic Lesions |
| No | TR-416 | 91-23-6 | o-Nitroanisole | Rats | F344/N | Female | Dosed-Feed | Urinary Bladder | Clear Evidence | Clear Evidence | (STOP STUDY) TRANSITIONAL CELL PAPILLOMA 0/58 2/59 1/60, TRANSITIONAL CELL CARCINOMA 0/58 28/59 48/60 | Neoplastic Lesions |
| No | TR-416 | 91-23-6 | o-Nitroanisole | Rats | F344/N | Male | Dosed-Feed | Urinary Bladder | Clear Evidence | Clear Evidence | (STOP STUDY) TRANSITIONAL CELL PAPILLOMA 0/59 9/59 1/60, TRANSITIONAL CELL CARCINOMA 0/59 27/59 50/60, SQUAMOUS CELL PAPILLOMA 0/59 0/59 4/60, SQUAMOUS CELL CARCINOMA 0/59 0/59 6/60, SARCOMA 0/59 2/59 9/60 | Neoplastic Lesions |
| Yes | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/60 2/60 3/60 50/60 | Neoplastic Lesions |
| Yes | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 4/60 17/60 55/60 60/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Female | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | (CECUM) CARCINOMA 0/60 1/60 4/60 3/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Male | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | (CECUM) CARCINOMA 0/60 12/60 9/60 0/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Female | Dosed-Feed | Liver | Clear Evidence | Equivocal Evidence | ADENOMA 1/60 0/59 1/60 6/60 | May Have Been Related |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | ADENOMA 7/60 5/59 19/59 29/60 CARCINOMA 2/60 4/59 6/59 16/60 COMBINED 9/60 9/59 24/59 39/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | ADENOMA 2/60 3/60 3/60 7/60 3/60 4/60 ADENOMA OR CARCINOMA 3/60 3/60 3/60 8/60 3/60 6/60 CHOLANGIOCARCINOMA 0/60 0/60 0/60 0/60 0/60 3/60 HEPATOCHOLANGIOCARCINOMA 0/60 1/60 0/60 1/60 0/60 0/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 5/60 1/60 2/60 3/60 8/60 OR ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 2/60 5/60 1/60 2/60 3/60 11/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 23/60 47/60 52/60 56/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 0/60 7/60 10/60 2/60 13/60 20/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MALIGNANT MESOTHELIOMA 2/60 20/60 29/60 44/60 44/60 54/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Female | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | (SUBCUTANEOUS) FIBROMA 3/60 3/60 18/60 20/60 FIBROMA OR FIBROSARCOMA 3/60 3/60 21/60 22/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | (SUBCUTANEOUS) LIPOMA 0/60 4/60 13/60 13/60 10/60 12/60 FIBROMA 5/60 46/60 52/60 59/60 45/60 52/60 FIBROSARCOMA 0/60 7/60 17/60 20/60 8/60 12/60 COMBINED 5/60 47/60 55/60 59/60 47/60 53/60 | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Rats | Sprague Dawley | Male | Gavage | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Female | Gavage | Heart | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Male | Gavage | Heart | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| Yes | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| Yes | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Female | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR CARCINOMA) | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Male | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR CARCINOMA) | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Rats | Sprague Dawley | Female | Gavage | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-465 | 77-09-8 | Phenolphthalein | Rats | F344/N | Male | Dosed-Feed | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | PHEOCHROMOCYTOMA 17/50 34/50 34/50 34/50 | Neoplastic Lesions |
| No | TR-465 | 77-09-8 | Phenolphthalein | Rats | F344/N | Female | Dosed-Feed | Adrenal Gland Medulla | Some Evidence | Some Evidence | PHEOCHROMOCYTOMA 3/50 11/50 9/50 2/49 OR MALIGNANT PHEOCHROMOCYTOMA 0/50 1/50 1/50 0/50 COMBINED 3/50 12/50 10/50 2/49 | Neoplastic Lesions |
| Yes | TR-465 | 77-09-8 | Phenolphthalein | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | HISTIOCYTIC SARCOMA 0/50 2/50 7/50 7/50; LYMPHOMA 15/50 28/50 33/5 25/50; LYMPHOMA (THYMIC ORIGIN) 1/50 9/50 10/50 7/50 | Neoplastic Lesions |
| Yes | TR-465 | 77-09-8 | Phenolphthalein | Mice | B6C3F1 | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | HISTIOCYTIC SARCOMA 1/50 3/50 11/50 12/49; LYMPHOMA (THYMIC ORIGIN) 0/50 4/50 7/50 2/49 | Neoplastic Lesions |
| No | TR-465 | 77-09-8 | Phenolphthalein | Rats | F344/N | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Clear Evidence | (SINGLE SECTIONS) ADENOMA 0/50 4/50 2/50 6/50 OR CARCINOMA 0/50 1/50 1/50 2/50 COMBINED 0/50 5/50 3/50 7/50; (SINGLE AND STEP SECTIONS) ADENOMA 1/50 10/50 15/50 15/50 OR CARCINOMA 0/50 1/50 2/50 2/50 COMBINED 1/50 10/50 16/50 16/50 | Neoplastic Lesions |
| No | TR-465 | 77-09-8 | Phenolphthalein | Mice | B6C3F1 | Female | Dosed-Feed | Ovary | Clear Evidence | Clear Evidence | BENIGN SEX-CORD STROMAL TUMOR 0/50 7/49 6/50 5/50 | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Brain | Positive | Positive | (NEUROBLASTOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Brain | Positive | Positive | (NEUROBLASTOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Brain | Positive | Positive | (NEUROBLASTOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Brain | Positive | Positive | (ADENOCARCINOMA, NEUROBLASTOMA, CARCINOMA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Uterus/Cervix | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-508 | 23246-96-0 | Riddelliine | Rats | F344/N | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA (ALL ORGANS) 12/50 8/50 13/50 18/50 18/50 14/50 | Neoplastic Lesions |
| Yes | TR-508 | 23246-96-0 | Riddelliine | Rats | F344/N | Male | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | Hematopoietic System: MONONUCLEAR CELL LEUKEMIA (ALL ORGANS) 2/50 9/50 | Neoplastic Lesions |
| No | TR-508 | 23246-96-0 | Riddelliine | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 2/50 1/50 0/50 2/50 31/50 | Neoplastic Lesions |
| No | TR-508 | 23246-96-0 | Riddelliine | Rats | F344/N | Female | Gavage | Liver | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 0/50 0/50 0/50 3/50 38/50; ADENOMA 1/50 0/50 0/50 0/50 1/50 7/50 | Neoplastic Lesions |
| No | TR-508 | 23246-96-0 | Riddelliine | Rats | F344/N | Male | Gavage | Liver | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 43/50; ADENOMA 0/50 4/50 | Neoplastic Lesions |
| No | TR-508 | 23246-96-0 | Riddelliine | Mice | B6C3F1 | Female | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 4/50 COMBINED 2/50 13/50 | Neoplastic Lesions |
| Yes | TR-311 | 127-18-4 | Tetrachloroethylene | Rats | F344/N | Male | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LEUKEMIA 28/50 37/50 37/50 | Neoplastic Lesions |
| Yes | TR-311 | 127-18-4 | Tetrachloroethylene | Rats | F344/N | Female | Inhalation | Hematopoietic System | Some Evidence | Some Evidence | LEUKEMIA 18/50 30/50 29/50 | Neoplastic Lesions |
| No | TR-311 | 127-18-4 | Tetrachloroethylene | Rats | F344/N | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 1/49 3/49 2/50 OR ADENOCARCINOMA 0/49 0/49 2/50 COMBINED 1/49 3/49 4/50 | Neoplastic Lesions |
| No | TR-311 | 127-18-4 | Tetrachloroethylene | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | CARCINOMA 1/48 13/50 36/50 | Neoplastic Lesions |
| No | TR-311 | 127-18-4 | Tetrachloroethylene | Mice | B6C3F1 | Male | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 11/49 8/49 18/50; CARCINOMA 7/49 25/49 26/50 | Neoplastic Lesions |
| Yes | TR-450 | 116-14-3 | Tetrafluoroethylene | Rats | F344/N | Male | Inhalation | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA: 34/50 43/50 38/50 31/50 | May Have Been Related |
| Yes | TR-450 | 116-14-3 | Tetrafluoroethylene | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | HISTIOCYTIC SARCOMA 1/48 21/48 19/47 18/48 | Neoplastic Lesions |
| Yes | TR-450 | 116-14-3 | Tetrafluoroethylene | Mice | B6C3F1 | Male | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | HISTIOCYTIC SARCOMA 0/48 12/48 7/48 7/48 | Neoplastic Lesions |
| Yes | TR-450 | 116-14-3 | Tetrafluoroethylene | Rats | F344/N | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA: 16/50 31/50 23/50 36/50 | Neoplastic Lesions |
| No | TR-450 | 116-14-3 | Tetrafluoroethylene | Rats | F344/N | Female | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | SINGLE SECTIONS: ADENOMA 0/50 3/50 1/50 3/50 OR CARCINOMA 0/50 0/50 0/50 2/50 COMBINED 0/50 3/50 1/50 5/50; SINGLE AND STEP SECTIONS: ADENOMA 0/50 3/50 3/50 8/50 OR CARCINOMA 0/50 0/50 0/50 3/50 COMBINED 0/50 3/50 3/50 10/50 | Neoplastic Lesions |
| No | TR-450 | 116-14-3 | Tetrafluoroethylene | Rats | F344/N | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | SINGLE SECTIONS: ADENOMA 0/50 0/50 6/50 3/50 OR CARCINOMA 1/50 0/50 2/50 0/50 COMBINED 1/50 0/50 6/50 3/50; SINGLE AND STEP SECTIONS: ADENOMA 2/50 4/50 9/50 13/50 OR CARCINOMA 1/50 1/50 2/50 0/50 COMBINED 3/50 5/50 9/50 13/50 | Neoplastic Lesions |
| No | TR-450 | 116-14-3 | Tetrafluoroethylene | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 15/48 17/48 20/47 15/47 OR CARCINOMA 4/48 28/48 22/47 20/47 COMBINED 17/48 33/48 29/47 28/47 | Neoplastic Lesions |
| No | TR-450 | 116-14-3 | Tetrafluoroethylene | Mice | B6C3F1 | Male | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 17/48 17/48 12/48 20/48 OR CARCINOMA 11/48 20/48 33/48 26/48 COMBINED 26/48 34/48 39/48 35/48 | Neoplastic Lesions |
| No | TR-450 | 116-14-3 | Tetrafluoroethylene | Rats | F344/N | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 0/50 4/50 5/50 6/50 OR CARCINOMA 0/50 4/50 9/50 2/50 COMBINED 0/50 7/50 12/50 8/50 | Neoplastic Lesions |
| No | TR-450 | 116-14-3 | Tetrafluoroethylene | Rats | F344/N | Male | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 3/50 6/50 8/50 5/50 OR CARCINOMA 1/50 1/50 10/50 3/50 COMBINED 4/50 7/50 15/50 8/50 | Neoplastic Lesions |
| No | TR-450 | 116-14-3 | Tetrafluoroethylene | Rats | F344/N | Male | Inhalation | Testis | Clear Evidence | Equivocal Evidence | INTERSTITIAL CELL ADENOMA 39/50 40/50 48/50 47/50 | May Have Been Related |
| No | TR-450 | 116-14-3 | Tetrafluoroethylene | Mice | B6C3F1 | Female | Inhalation | Vascular System (Liver) | Clear Evidence | Clear Evidence | HEMANGIOMA 0/48 5/48 2/47 1/47 OR HEMANGIOSARCOMA 0/48 27/48 27/47 34/47 COMBINED 0/48 31/48 28/47 35/47 | Neoplastic Lesions |
| No | TR-450 | 116-14-3 | Tetrafluoroethylene | Mice | B6C3F1 | Male | Inhalation | Vascular System (Liver) | Clear Evidence | Clear Evidence | HEMANGIOMA 0/48 10/48 5/48 2/48 OR HEMANGIOSARCOMA 0/48 21/48 27/48 37/48 COMBINED 0/48 26/48 30/48 38/48 | Neoplastic Lesions |
| No | TR-450 | 116-14-3 | Tetrafluoroethylene | Rats | F344/N | Female | Inhalation | Vascular System (Liver) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 0/50 5/50 1/50 | Neoplastic Lesions |
| No | TR-391 | 115-96-8 | Tris(2-Chloroethyl) Phosphate | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Equivocal Evidence | Equivocal Evidence | ADENOMA 3/50 7/50 7/50 OR CARCINOMA 0/50 1/50 0/50 COMBINED 3/50 8/50 7/50 | Neoplastic Lesions |
| Yes | TR-391 | 115-96-8 | Tris(2-Chloroethyl) Phosphate | Rats | F344/N | Female | Gavage | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 14/50 16/50 20/50 | May Have Been Related |
| Yes | TR-391 | 115-96-8 | Tris(2-Chloroethyl) Phosphate | Rats | F344/N | Male | Gavage | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 5/50 14/50 13/50 | May Have Been Related |
| No | TR-391 | 115-96-8 | Tris(2-Chloroethyl) Phosphate | Rats | F344/N | Female | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 5/50 | Neoplastic Lesions |
| No | TR-391 | 115-96-8 | Tris(2-Chloroethyl) Phosphate | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 1/50 5/50 24/50 | Neoplastic Lesions |
| No | TR-391 | 115-96-8 | Tris(2-Chloroethyl) Phosphate | Mice | B6C3F1 | Male | Gavage | Kidney Tubular Cell | Equivocal Evidence | Equivocal Evidence | ADENOMA 1/50 1/50 3/50 | Neoplastic Lesions |
| No | TR-391 | 115-96-8 | Tris(2-Chloroethyl) Phosphate | Rats | F344/N | Female | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 1/50 1/50 1/50 OR CARCINOMA 0/50 2/50 3/50 COMBINED 1/50 3/50 4/50 | May Have Been Related |
| No | TR-391 | 115-96-8 | Tris(2-Chloroethyl) Phosphate | Rats | F344/N | Male | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 1/50 2/48 3/50 OR CARCINOMA 0/50 0/48 2/50 COMBINED 1/50 2/48 5/50 | May Have Been Related |
| Yes | TR-058 | 52-24-4 | tris(Aziridinyl)-phosphine sulfide (Thio-TEPA) | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA, LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-058 | 52-24-4 | tris(Aziridinyl)-phosphine sulfide (Thio-TEPA) | Mice | B6C3F1 | Male | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA, LEUKEMIA) | Neoplastic Lesions |
| Yes | TR-058 | 52-24-4 | tris(Aziridinyl)-phosphine sulfide (Thio-TEPA) | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-058 | 52-24-4 | tris(Aziridinyl)-phosphine sulfide (Thio-TEPA) | Mice | B6C3F1 | Male | Intraperitoneal Injection | Preputial Gland | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-058 | 52-24-4 | tris(Aziridinyl)-phosphine sulfide (Thio-TEPA) | Mice | B6C3F1 | Male | Intraperitoneal Injection | Skin | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-058 | 52-24-4 | tris(Aziridinyl)-phosphine sulfide (Thio-TEPA) | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Skin | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-058 | 52-24-4 | tris(Aziridinyl)-phosphine sulfide (Thio-TEPA) | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Skin | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-058 | 52-24-4 | tris(Aziridinyl)-phosphine sulfide (Thio-TEPA) | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Zymbal Gland | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-058 | 52-24-4 | tris(Aziridinyl)-phosphine sulfide (Thio-TEPA) | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Zymbal Gland | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| Yes | TR-537 | 631-64-1 | Water disinfection byproducts (Dibromoacetic acid) | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Some Evidence | Some Evidence | MONONUCLEAR CELL LEUKEMIA (ALL ORGANS) 11/50 13/50 16/50 22/50 | Neoplastic Lesions |
| Yes | TR-537 | 631-64-1 | Water disinfection byproducts (Dibromoacetic acid) | Rats | F344/N | Male | Dosed-Water | Hematopoietic System | Some Evidence | Some Evidence | MALIGNANT MESOTHELIOMA (ALL ORGANS) 3/50 1/50 0/50 10/50 | Neoplastic Lesions |
| No | TR-537 | 631-64-1 | Water disinfection byproducts (Dibromoacetic acid) | Mice | B6C3F1 | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | ADENOMA 19/49 26/50 32/50 35/49 CARCINOMA 3/49 3/50 12/50 8/49 COMBINED 22/49 28/50 37/50 37/49 | Neoplastic Lesions |
| No | TR-537 | 631-64-1 | Water disinfection byproducts (Dibromoacetic acid) | Mice | B6C3F1 | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | ADENOMA 18/49 37/50 37/50 42/50 CARCINOMA 14/49 9/50 19/50 26/50 COMBINED 28/49 41/50 42/50 47/50 HEPATOBLASTOMA 0/49 4/50 6/50 18/50 | Neoplastic Lesions |
| No | TR-537 | 631-64-1 | Water disinfection byproducts (Dibromoacetic acid) | Mice | B6C3F1 | Female | Dosed-Water | Lung | Clear Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 3/50 3/50 6/50 ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 2/50 5/50 5/50 7/50 | May Have Been Related |
| No | TR-537 | 631-64-1 | Water disinfection byproducts (Dibromoacetic acid) | Mice | B6C3F1 | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 7/49 5/50 17/50 12/50 ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 12/49 12/50 22/50 17/50 | Neoplastic Lesions |